IDO1 and depressive symptom measurement: After intracerebroventricular injection of Aβ1-42 polypeptide, the level of IDO in the prefrontal cortex and hippocampus, as well as the levels of KYN and KYN/Trp are increased, which is accompanied by memory impairment, depression, and anxiety-like behaviors.